Table 2.
MMP-12 gene polymorphism -82 A-to-G impact on lung function of COPD patients and healthy control groups
| Genotypes MMP-12-82A > G | COPD patients | CTR | CTR smokers | CTR non-smokers | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 355 | N = 309 | N = 110 | N = 199 | |||||||||
| N | FEV1 (% predict.) |
FEV1/FVC (% predict.) |
N | FEV1 (% predict.) |
FEV1/FVC (% predict.) |
N | FEV1 (% predict.) |
FEV1/FVC (% predict.) |
N | FEV1 (% predict.) |
FEV1/FVC (% predict.) |
|
| A allele | 333 | 55.5 ± 18.6 | 52.3 ± 16.0 | 297 | 92.0 ± 23.4 | 86.2 ± 23.2 | 105 | 92.8 ± 21.8 | 92.0 ± 19.5 | 192 | 91.5 ± 23.3 | 85.8 ± 24.5 |
| G allele | 82 | 54.1 ± 15.8 | 51.4 ± 17.9 | 93 | 92.1 ± 20.7 | 92.8 ± 24.7 | 14 | 94.9 ± 21.9 | 90.7 ± 20.6 | 49 | 88.5 ± 20.4 | 95.8 ± 27.8 |
| AA | 253 | 55.9 ± 19.3 | 52.5 ± 15.4 | 216 | 92.0 ± 23.4 | 86.2 ± 23.2 | 66 | 92.0 ± 22.2 | 92.8 ± 18.5 | 150 | 91.8 ± 24.2 | 85.3 ± 26.5 |
| AG | 80 | 53.9 ± 18.0 | 51.7 ± 18.1 | 81 | 92.6 ± 20.1 | 91.9 ± 21.7 | 39 | 94.0 ± 21.4 | 91.5 ± 21.2 | 42 | 90.0 ± 19.9 | 93.4 ± 22.3 |
| GG | 2 | 56.7 ± 17.4 | 44.9 ± 18.5 | 12 | 88.5 ± 25.3 | 99.2 ± 40.2 | 5 | 101.0 ± 22.6 | 84.3 ± 15.9 | 7 | 79.7 ± 22.3 | 109.9 ± 47.8 |
| P value* | 0.71 | 0.90 | 0.95 | 0.10 | 0.75 | 0.26 | 0.30 | 0.77 | ||||
N number of individuals/alleles/genotypes, COPD chronic obstructive pulmonary disease groups, CTR control group, FEV1 forced expiratory volume in 1 s, FEV1/FVC Tiffeneau-Pinelli index – ratio of forced expiratory volume in 1 s and forced vital capacity; *, no significant difference in mean of lung function parameters between carriers with different −82 A > G alleles/genotypes in one-way ANOVA test, Tuckey post-hoc test were not conducted